Related Experiment Video
Updated: May 26, 2026

Detection of Bacteria Using Fluorogenic DNAzymes
Published on: May 28, 2012
The role of enzymology in a structure-based drug discovery program: bacterial DNA gyrase
1Trius Therapeutics, San Diego, CA, USA. mcunningham@triusrx.com
Abstract:
The capability to accurately, rapidly, and reproducibly determine the affinity of a ligand for a target protein or enzyme is a vital component for a successful structure-based drug design effort. In order to successfully drive a structure-based drug design (SBDD) project forward, multiple distinct assays, each with particular strengths and weaknesses, need to be employed. Using bacterial DNA gyrase as an example, a range of assays are described that will fully support an SBDD program.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
DNA Helicases
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Restriction Enzymes
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
Inhibitors of Bacterial Protein Synthesis
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...

